|
The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: ---------- Feedback PLC - London-based provider of software and systems for use in clinical settings - Reports final results for the year ended May 31. Revenue decreases to £885,623 from £1.2 million the year before. Pretax loss widens to £7.3 million from £3.6 million. Cash & equivalents balance is £5.9 million as of May 31, up from £3.9 million one year prior. Loss before interest, tax, depreciation and amortisation widens to £3.1 million from £2.7 million. Non-Executive Chair Rory Shaw says that ‘ongoing disruption across the NHS has meant revenue growth has not reached the levels we anticipated’ but that ‘the government’s overall vision for the future of the NHS remains strongly aligned with the company’s offering’. ‘The NHS’s restructuring has presented an unforeseen challenge, but once the sector stabilises, Feedback is well positioned to deliver the clinician collaboration solutions that are essential to unlocking the productivity gains the NHS urgently needs,’ he adds. ---------- KRM22 PLC - London-based technology and software investment company - Total revenue for the six months ended June 30 rises 11% on-year to £3.6 million from £3.3 million, with recurring revenue growing 15% to £3.4 million from £2.9 million. Annualised recurring revenue climbs 20% to £7.2 million from £6.0 million. Pretax loss widens to £1.6 million from £1.3 million. Unrealised foreign exchange loss widens to £1.1 million from £8,000. ‘This momentum is being driven by sustained demand for Risk Manager and Limits Manager, with the majority of new ARR coming from cross-selling, highlighting both the strength of our applications and the quality of our service,’ says Chief Executive Dan Carter. Company says ARR totals £7.4 million as of Wednesday, and notes a ‘significant share of new ARR generated in H1 2025 from existing clients expanding into additional applications’. ‘Looking ahead, our pipeline remains robust as we work towards a strong close to 2025,’ Carter says. ---------- McBride PLC - Manchester, England-based private label products manufacturer - Pretax profit for the year ended June 30 increases 2.5% to £49.0 million from £46.5 million the previous year. Revenue, however, decreases 0.9% to £926.5 million from £934.8 million but rises 0.7% at constant currency ‘with volume growth from both private label and contract manufacturing’. Company also reports finance costs decreasing to £11.2 million from £17.8 million, while administrative costs decrease to £197.0 million from £202.1 million. Reinstates annual dividends, declaring a 3.0 pence per share final payout, saying the restart is due to its ‘solid trading performance’ and the refinancing of its debt facilities ‘with significantly improved terms’ in November. McBride says it enters financial 2026 ‘from a position of strength’, expecting to achieve volume growth through contract wins and seeing volumes in line with its forecasts in the first few months. ‘McBride has delivered another year of strong operational and financial results, marking five consecutive half years of these materially improved profitability levels...The reinstatement of dividends reflects our confidence in the business’s trajectory and our commitment to delivering long-term shareholder value,’ comments CEO Chris Smith. ‘These results demonstrate the strength of our core activities and our normalised financial situation, positioning us well for continued growth and investment.’ ---------- Fusion Antibodies PLC - Belfast-based contract researcher providing therapeutic antibody discovery, design and optimisation services to the healthcare market - Says the National Cancer Institute has asked to extend its use of the OptiMAL platform, under its collaboration agreement with Fusion announced in late 2023, ‘for use against further targets in the coming years’. The partnership is currently due to continue until November this year, but Fusion says negotiations are underway ‘to establish mutually agreeable terms’ for an extension. Notes that it announced in January that the NCI had identified several antibody-expressing cells as positively binding to three targets of interest, with Fusion to verify the binding. On Wednesday, Fusion confirms that the antibodies produced do bind each of their targets, with binding affinities within the expected range for commercially viable antibodies. This included multiple ‘hits with estimated affinities in the single digit nM range’. ‘This exceeded our expectations and is a good selling point for the OptiMAL platform,’ Fusion says. Adds that the NCI has now validated the functions of the recombinantly produced antibodies against human cells, that OptiMAL succeeded in identifying hits against two of the most commonly used antigen types, and that screening has also identified weaker binders, ‘confirming the OptiMAL platform’s suitability for use against a wide range of target product profiles’. ---------- Prospex Energy PLC - investment firm focused on European gas and power projects - Announces delay to the resumption of production in the Viura gas field, northern Spain, following the completed workover of the Viura-1B well. Says this is due to ‘an unforeseen event during the well testing’ last month. Explains that a pressure control equipment failure ‘required the safe and controlled cutting of the associated cable while still inside the well’. A wireline logging tool and its cable were left inside the tubing, and the equipment needed to remove them had to be mobilised from Aberdeen, Scotland. Operations for the removal started on Tuesday. Prospex says the timing for resuming production is unknown. Prospex owns 7.24% of the Viura field through its 7.5% stake in the field’s operator, HEYCO Energy Iberia SL, and is accruing 14.47% of Viura’s production income until its capital investment is repayed with the agreed interest. ‘This is a very unfortunate setback in re-instating production from this prolific gas field,’ comments Prospex CEO Mark Routh. ‘Safety of production operations is paramount and the operator is working as quickly as it can to resume gas production from the field at stable and sustainable rates, but this has to be done safely.’ ---------- Premier African Minerals Ltd - developer of RHA tungsten and Zulu lithium and tantalum projects in Zimbabwe - Updates on the plant status of the Zulu projects following completion, as announced in August, of the commissioning test phase. Says the next intended step is a further test run focusing on the optimising aspects of the flotation plant, to ensure that saleable concentrate, in other words spodumene concentrate with more than 5% lithium oxide, is continuously produced. Says the plant has achieved this ‘on numerous occasions’ but the new testing must demonstrate that it can do so consistently. Says Zulu has restarted limited mining to ensure a continuous supply of ore to the run-of-mine pad. ‘This next phase is a fundamental step in the ongoing validation process of the operating capacity of the Zulu plant,’ says Managing Director Graham Hill. ‘Demonstrating the ability to consistently float material at grade over sustained periods is essential to ensuring that all operational aspects are aligned for the future of Zulu. These results will provide the foundation for growth, whether through new investment or additional off-take funding, as those discussions with potential funders continue to advance.’ ---------- Altona Rare Earths PLC - African critical raw materials-focused resource explorer and developer - Receives results from metallurgical testing of a fluorspar ore sample containing gallium at the multi-commodity Monte Muambe project in northwestern Mozambique. Says these confirm that the flotation process will lead to a separation of fluorspar in the concentrate, and gallium in the process tailings. This provides a potential pathway to recover both fluorspar and gallium, and Altona says the planned JORC mineral resource estimate expected this year will report both commodities. Also, it says drilling of hole MM111 has commenced and expects it to intercept both fluorspar and gallium mineralisation. Expects results from 280 soil samples sent for fluorine assays to lead to the discovery of further fluorspar resources, which it will then include in the drilling plan. ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
